Advanced Screening Approaches in Drug Discovery
Online Symposium
23 October 2024 | Online, BST (UTC+1)
Bringing together key opinion leaders from across the globe for focused discussions on using the latest screening technologies in drug discovery
Sponsored By
Concept Life Sciences is a UK-based drug discovery CRO , helping global pharma and biotech companies accelerate their drug candidate to clinic by offering integrated drug discovery programs as well as high quality solutions in Biology, Chemistry, ADME/ DMPK, Toxicology and GMP manufacturing. Concept Life Sciences has helped pharma and biotech companies accelerate 30 candidates to preclinical stage, 21 candidates to clinic, and 4 candidates to market. Visit our website to learn more: Concept Life Sciences | From Concept through to Clinic.
Key Topics Covered
- Fragment screening platforms
- CRISPR screening
- Phenotypic screening
- Target-based
- Virtual & structure-based approaches
- Advanced cell screening
Benefits of Attending
- Meet with global key innovators in a focused symposium to hear the latest case studies in utilizing advanced screening approaches for drug target identification & validation. This programme takes a deep dive into best practice screening approaches & technological advancements, bringing together thought leaders from across the globe for focused discussions & networking
- Stay at the forefront of innovation by hearing about the latest advancements, cutting-edge techniques, and emerging trends in fragment-based and CRISPR screening approaches used to identify and validate novel drug targets
- Discuss the latest developments in improved cell screening platforms to advance drug discovery efforts and virtual & structure-based approaches to screening
- Followed by the release of the ‘Harnessing Advanced Screening Approaches for Drug Target Identification & Validation’ report detailing key insights, methodologies, and emerging trends discussed during the event for leveraging drug discovery screening approaches effectively
Latest Resources
GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
GHR’s total investment in C2N has now broken $50 million since 2020.
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.
Meet Our Expert Speakers
Advanced Screening Approaches in Drug Discovery Online Symposium again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Confirmed speakers include:
Leire Escudero-Ibarz
Associate Director,
AstraZeneca
Linda Kitching
Associate Director,
AstraZeneca
Nazia Parvez
Investigator,
GSK
Register Your Interest
Submit your details and a member of our team will be in touch